Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company was founded in 2007 and is headquartered in Beijing, China.
Stock data | 2024 | Change |
---|---|---|
Price | $0.8257963035784506 | N/A |
Market Cap | $331.14M | N/A |
Shares Outstanding | 401.00M | N/A |
Employees | 658.00 | N/A |